Literature DB >> 12870063

Penicillin at the late stage of leptospirosis: a randomized controlled trial.

Everaldo Costa1, Antonio Alberto Lopes, Edilson Sacramento, Yara Aragão Costa, Eliana Dias Matos, Marcelo Barreto Lopes, José Carlos Bina.   

Abstract

There is evidence that an early start of penicillin reduces the case-fatality rate of leptospirosis and that chemoprophylaxis is efficacious in persons exposed to the sources of leptospira. The existent data, however, are inconsistent regarding the benefit of introducing penicillin at a late stage of leptospirosis. The present study was developed to assess whether the introduction of penicillin after more than four days of symptoms reduces the in-hospital case-fatality rate of leptospirosis. A total of 253 patients aged 15 to 76 years with advanced leptospirosis, i.e., more than four days of symptoms, admitted to an infectious disease hospital located in Salvador, Brazil, were selected for the study. The patients were randomized to one of two treatment groups: with intravenous penicillin, 6 million units day (one million unit every four hours) for seven days (n = 125) and without (n = 128) penicillin. The main outcome was death during hospitalization. The case-fatality rate was approximately twice as high in the group treated with penicillin (12%; 15/125) than in the comparison group (6.3%; 8/128). This difference pointed in the opposite direction of the study hypothesis, but was not statistically significant (p = 0.112). Length of hospital stay was similar between the treatment groups. According to the results of the present randomized clinical trial initiation of penicillin in patients with severe forms of leptospirosis after at least four days of symptomatic leptospirosis is not beneficial. Therefore, more attention should be directed to prevention and earlier initiation of the treatment of leptospirosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870063     DOI: 10.1590/s0036-46652003000300005

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  12 in total

1.  A rare case of Weil's disease with alveolar haemorrhage.

Authors:  Abhiram Chakrabarti; Manab Nandy; Dipankar Pal; Sudesna Mallik
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

Review 2.  Clinical and imaging manifestations of hemorrhagic pulmonary leptospirosis: a state-of-the-art review.

Authors:  Edson Marchiori; Sílvia Lourenço; Sérgio Setúbal; Gláucia Zanetti; Taisa Davaus Gasparetto; Bruno Hochhegger
Journal:  Lung       Date:  2010-12-09       Impact factor: 2.584

3.  Clinical profile, management and outcome of patients with leptospirosis during the times of COVID-19 pandemic: A prospective study from a tertiary care centre in South India.

Authors:  Nitin Gupta; William Wilson; Prithvishree Ravindra; Sowmya Joylin; Rachana Bhat; Kavitha Saravu
Journal:  Infez Med       Date:  2021-09-10

4.  Nucleic acid and antigen detection tests for leptospirosis.

Authors:  Bada Yang; Sophia G de Vries; Ahmed Ahmed; Benjamin J Visser; Ingeborg M Nagel; René Spijker; Martin P Grobusch; Rudy A Hartskeerl; Marga Ga Goris; Mariska Mg Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2019-08-01

5.  Cardiac Magnetic Resonance of Myocardial Involvement in Leptospirosis.

Authors:  Onkar B Auti; Kanav Kansal; K V Shrikanth; Vimal Raj
Journal:  Heart Views       Date:  2017 Oct-Dec

6.  Comparing antibiotic treatment for leptospirosis using network meta-analysis: a tutorial.

Authors:  Cho Naing; Simon A Reid; Kyan Aung
Journal:  BMC Infect Dis       Date:  2017-01-05       Impact factor: 3.090

Review 7.  The Jarisch-Herxheimer reaction in leptospirosis: a systematic review.

Authors:  Gilles Guerrier; Eric D'Ortenzio
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

8.  Antibiotics for the treatment of leptospirosis: systematic review and meta-analysis of controlled trials.

Authors:  Jaykaran Charan; Deepak Saxena; Summaiya Mulla; Preeti Yadav
Journal:  Int J Prev Med       Date:  2013-05

9.  Risk factors for intensive care unit admission in patients with severe leptospirosis: a comparative study according to patients' severity.

Authors:  Elizabeth De Francesco Daher; Douglas Sousa Soares; Anna Tereza Bezerra de Menezes Fernandes; Marília Maria Vasconcelos Girão; Pedro Randal Sidrim; Eanes Delgado Barros Pereira; Natalia Albuquerque Rocha; Geraldo Bezerra da Silva
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

10.  Pharmacokinetics of enrofloxacin HCl-2H2O (Enro-C) in dogs and pharmacokinetic/pharmacodynamic Monte Carlo simulations against Leptospira spp.

Authors:  Hector Sumano; Luis Ocampo; Graciela Tapia; Corazon de Jesus Mendoza; Lilia Gutierrez
Journal:  J Vet Sci       Date:  2018-09-30       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.